Clinical Trials Logo
  1. Home
  2. Sars-CoV2
  3. NCT04438941

Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic — COVID-PRONE  

Sars-CoV2 Clinical Trial

Official title:
Contribution of a Prone Team in Intensive Care During the Covid-19 Epidemic

Clinical Trial Summary

SARS-CoV-2 induced by COVID 19, involved the hospitalization of 101,932 patients in France, including 4,007 in intensive care (source: Santé Publique France). Alsace was one of the most affected regions on the metropolitan territory with a large number of patients hospitalized at the University Hospital of Strasbourg.

In view of the seriousness of the epidemic and the rapid arrival of new patients requiring mechanical ventilation, 3 new intensive care units have been created on the NHC site alone, making it possible to accommodate a maximum of 111 patients (compared to 52 during normal periods).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04438941
Study type Observational
Source University Hospital, Strasbourg, France
Contact Bob HEGER, MD
Phone 33 3.69.55.04.43
Email Bob.Heger@chru-strasbourg.fr
Status Recruiting
Phase
Start date March 25, 2020
Completion date June 20, 2020
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04446065 - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers Phase 2/Phase 3
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT04463004 - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation Phase 2
Completed NCT04446429 - Anti-Androgen Treatment for COVID-19 N/A
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2
Recruiting NCT04581148 - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Recruiting NCT04441372 - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Terminated NCT04371978 - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19 Phase 3
Completed NCT04530604 - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS) Phase 1
Active, not recruiting NCT04635605 - Methylene Blue Treatment of COVID-19 Phase 2
Recruiting NCT04395599 - Risk of Air Contamination During Visceral Surgery in COVID19 Patients N/A
Recruiting NCT04472585 - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients Phase 1/Phase 2
Active, not recruiting NCT04411433 - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 Phase 3
Completed NCT04359706 - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting NCT04395794 - SARS-CoV-2 Disguise Study
Completed NCT04386551 - Detection of COVID-19 in Saliva Collection
Recruiting NCT04403269 - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE Phase 2
Withdrawn NCT04379492 - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 Phase 2
Completed NCT04366934 - Study of the Pathogenesis of Olfactory Disorders in COVID-19